Nasdaq · CIK 0001434647
ZVRA ZEVRA THERAPEUTICS, INC.
Insider trading from SEC Form 4. Last filing Aug 17, 2026. Close $11.39 on Oct 9, 2026, +41% from the 52-week low and -23% from the high.
In brief
ZEVRA THERAPEUTICS, INC. (ZVRA) has 40 SEC Form 4 filings on file from 14 insiders, the latest filed on Aug 17, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 2 open-market sells worth $613k, net -$613k.
20 open-market trades have been scored at ZVRA. The newest: Rahsaan Thompson (Chief Legal & Compliance) sold $475k of stock on Aug 14, 2026, filed Aug 17, 2026, scored 40 (moderate), under a 10b5-1 plan. The largest of the 20 shown: Neil F. McFarlane (President and CEO) sold $853k on Feb 2, 2026, scored 33 (weak), under a 10b5-1 plan. 2 insiders sold within 14 days of each other around Aug 14, 2026.
16 Form 144 notices of planned sales are on file, the latest filed Aug 14, 2026.
Last 90 days
Net insider value
-$613k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
2
$613k by 2 insiders
Insiders on file
14
with a Form 4 at this company
Price and insider trades, last year
ZVRAOct 9, 2026 · close 11.39
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at ZEVRA THERAPEUTICS, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Rahsaan Thompson Chief Legal & Compliance sell | $475k 42,666 shares | -53% | +57% from low-23% from high | |
| 39Weak | Corey Michael Watton director sell | $138k 12,300 shares | -87% | +59% from low-22% from high | |
| 7Weak | Rahsaan Thompson Chief Legal & Compliance sell | $438k 34,557 shares | -30% | +75% from low-7% from high | |
| 0Weak | Rahsaan Thompson Chief Legal & Compliance sell | $20k 1,794 shares | -4% | +49% from low-16% from high | |
| 16Weak | Neil F. McFarlane President and CEO sell | $125k 14,625 shares | -4% | +31% from low-33% from high | |
| 15Weak | Timothy J. Sangiovanni SVP, Finance & Corp Controller sell | $28k 3,000 shares | -9% | +40% from low-28% from high | |
| 25Weak | Joshua Schafer CCO sell | $97k 10,500 shares | -14% | +40% from low-28% from high | |
| 33Weak | Neil F. McFarlane President and CEO sell | $853k 91,000 shares | -20% | +43% from low-27% from high | |
| 11Weak | Adrian W Quartel Chief Medical Officer sell | $40k 4,533 shares | -32% | +37% from low-30% from high | |
| 0Weak | Timothy J. Sangiovanni SVP, Finance & Corp Controller sell | $15k 1,750 shares | -8% | +37% from low-30% from high | |
| 0Weak | Joshua Schafer CCO sell | $30k 3,375 shares | -8% | +37% from low-30% from high | |
| 1Weak | Rahsaan Thompson Chief Legal & Compliance sell | $36k 4,080 shares | -8% | +37% from low-30% from high | |
| 12Weak | Neil F. McFarlane President and CEO sell | $211k 19,500 shares | -8% | +68% from low-14% from high | |
| 41Moderate | Tamara A Favorito director buy | $25k 3,175 shares | +442% | +18% from low-39% from high | |
| 50Moderate | Alvin Shih director buy | $158k 20,000 shares | - | +18% from low-39% from high | |
| 28Weak | John B Bode director buy | $46k 5,000 shares | +13% | +37% from low-30% from high | |
| 17Weak | Rahsaan Thompson Chief Legal & Compliance sell | $221k 24,000 shares | -36% | +41% from low-4% from high | |
| 30Weak | John B Bode director buy | $80k 10,000 shares | +33% | - | |
| 16Weak | R. LaDuane Clifton CFO & Treasurer sell | $86k 11,000 shares | -18% | - | |
| 25Weak | Corey Michael Watton director buy | $3,958 500 shares | +50% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 14, 2026 | RAHSAAN THOMPSON Officer, Secretary | 42,666 0.07% of outstanding | $477k | Aug 14, 2026 | $438k |
| Jul 8, 2026 | JOHN BODE Director | 10,516 0.02% of outstanding | $156k | Jul 8, 2026 | none |
| May 11, 2026 | Rahsaan Thompson Officer, Chief Legal & Compliance / Secretary | 36,351 0.06% of outstanding | $405k | May 11, 2026 | none |
| Mar 16, 2026 | RAYMOND L CLIFTON Officer | 345,428 0.59% of outstanding | $3.4M | Mar 16, 2026 | $127k |
| Feb 2, 2026 | NEIL F MCFARLANE Director, Officer | 105,625 0.19% of outstanding | $951k | Feb 2, 2026 | none |
| Jan 30, 2026 | R LaDuane Clifton Former CFO & Treasurer | 14,000 0.02% of outstanding | $124k | Jan 30, 2026 | none |
| Jan 30, 2026 | ADRIAN QUARTEL Officer | 4,533 0.01% of outstanding | $40k | Jan 30, 2026 | none |
| Jan 30, 2026 | TIMOTHY SANGIOVANNI Officer | 4,750 0.01% of outstanding | $42k | Jan 30, 2026 | none |
| Jan 30, 2026 | JOSHUA SCHAFER Officer | 13,875 0.02% of outstanding | $123k | Jan 30, 2026 | none |
| Jan 30, 2026 | RAHSAAN THOMPSON Officer, Secretary | 4,080 0.01% of outstanding | $36k | Jan 30, 2026 | none |
| Oct 10, 2025 | NEIL F MCFARLANE Director, Officer | 19,500 0.03% of outstanding | $211k | Oct 10, 2025 | none |
| Jun 26, 2025 | RAHSAAN THOMPSON Officer, Secretary | 24,000 0.04% of outstanding | $224k | Jun 26, 2025 | none |
| Feb 13, 2025 | R. LADUANE CLIFTON Officer | 11,000 0.02% of outstanding | $85k | Feb 13, 2025 | none |
| Feb 13, 2025 | NEIL F MCFARLANE Director, Officer | 91,817 0.17% of outstanding | $709k | Feb 13, 2025 | none |
| Feb 13, 2025 | Timothy Sangiovanni Officer | 3,000 0.01% of outstanding | $23k | Feb 13, 2025 | none |
| Feb 13, 2025 | Joshua Schafer Officer | 10,500 0.20% of outstanding | $81k | Feb 13, 2025 | none |
Transactions
The newest 50 of 82 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | Rahsaan Thompson Chief Legal & Compliance | SOpen-market sale Common Stock10b5-1 | -42,666 | $11.13 | $475k | 37,569 | Aug 17, 2026 |
| Aug 10, 2026 | Corey Michael Watton director | MOption exercise Common Stock | +12,300 | $4.97 | $61k | 14,100 | Aug 12, 2026 |
| Aug 10, 2026 | Corey Michael Watton director | SOpen-market sale Common Stock | -12,300 | $11.25 | $138k | 1,800 | Aug 12, 2026 |
| Aug 10, 2026 | Corey Michael Watton director | MOption exercise Stock Option (right to buy)derivative | -12,300 | $0.00 | $0 | 46,500 | Aug 12, 2026 |
| Jun 21, 2026 | Rahsaan Thompson Chief Legal & Compliance | MOption exercise Common Stock10b5-1 | +66,667 | - | - | 114,792 | Jun 23, 2026 |
| Jun 22, 2026 | Rahsaan Thompson Chief Legal & Compliance | SOpen-market sale Common Stock10b5-1 | -34,557 | $12.68 | $438k | 80,235 | Jun 23, 2026 |
| Jun 21, 2026 | Rahsaan Thompson Chief Legal & Compliance | MOption exercise Restricted Stock Unitderivative10b5-1 | -66,667 | $0.00 | $0 | 66,667 | Jun 23, 2026 |
| Jun 4, 2026 | Corey Michael Watton director | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 18, 2026 |
| Jun 4, 2026 | Alicia Secor director | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 18, 2026 |
| Jun 4, 2026 | Thomas Anderson director | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 18, 2026 |
| Jun 4, 2026 | Tamara A Favorito director | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 18, 2026 |
| Jun 4, 2026 | Alvin Shih director | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 18, 2026 |
| Jun 4, 2026 | Douglas W Calder director | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 18, 2026 |
| May 28, 2026 | Timothy J. Sangiovanni SVP, Finance & Corp Controller | AGrant or award Stock Option (right to buy)derivative | +40,000 | $0.00 | $0 | 40,000 | May 29, 2026 |
| May 28, 2026 | Timothy J. Sangiovanni SVP, Finance & Corp Controller | AGrant or award Restricted Stock Unitderivative | +20,000 | $0.00 | $0 | 20,000 | May 29, 2026 |
| May 11, 2026 | Rahsaan Thompson Chief Legal & Compliance | SOpen-market sale Common Stock10b5-1 | -1,794 | $11.30 | $20k | 48,125 | May 13, 2026 |
| Mar 24, 2026 | John B Bode director | MOption exercise Common Stock | +39,200 | $4.97 | $195k | 84,200 | Mar 26, 2026 |
| Mar 24, 2026 | John B Bode director | MOption exercise Common Stock | +39,200 | $4.89 | $192k | 123,400 | Mar 26, 2026 |
| Mar 24, 2026 | John B Bode director | MOption exercise Stock Option (right to buy)derivative | -39,200 | $0.00 | $0 | 19,600 | Mar 26, 2026 |
| Mar 24, 2026 | John B Bode director | MOption exercise Stock Option (right to buy)derivative | -39,200 | $0.00 | $0 | 0 | Mar 26, 2026 |
| Mar 18, 2026 | Justin A Renz CFO | AGrant or award Stock Option (right to buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Mar 19, 2026 |
| Feb 7, 2026 | Neil F. McFarlane President and CEO | MOption exercise Common Stock10b5-1 | +37,500 | - | - | 401,850 | Feb 10, 2026 |
| Feb 9, 2026 | Neil F. McFarlane President and CEO | SOpen-market sale Common Stock10b5-1 | -14,625 | $8.56 | $125k | 387,225 | Feb 10, 2026 |
| Feb 7, 2026 | Neil F. McFarlane President and CEO | MOption exercise Restricted Stock Unitderivative10b5-1 | -37,500 | $0.00 | $0 | 75,000 | Feb 10, 2026 |
| Feb 3, 2026 | Joshua Schafer CCO | SOpen-market sale Common Stock10b5-1 | -10,500 | $9.19 | $97k | 62,278 | Feb 4, 2026 |
| Feb 3, 2026 | Timothy J. Sangiovanni SVP, Finance & Corp Controller | SOpen-market sale Common Stock10b5-1 | -3,000 | $9.18 | $28k | 29,590 | Feb 4, 2026 |
| Jan 30, 2026 | Adrian W Quartel Chief Medical Officer | MOption exercise Common Stock10b5-1 | +11,333 | - | - | 14,256 | Feb 2, 2026 |
| Jan 30, 2026 | Timothy J. Sangiovanni SVP, Finance & Corp Controller | MOption exercise Common Stock10b5-1 | +6,333 | - | - | 22,674 | Feb 2, 2026 |
| Jan 30, 2026 | Joshua Schafer CCO | MOption exercise Common Stock10b5-1 | +11,333 | - | - | 40,819 | Feb 2, 2026 |
| Jan 30, 2026 | Rahsaan Thompson Chief Legal & Compliance | MOption exercise Common Stock10b5-1 | +11,333 | - | - | 53,999 | Feb 2, 2026 |
| Jan 31, 2026 | Neil F. McFarlane President and CEO | MOption exercise Common Stock10b5-1 | +233,334 | - | - | 455,350 | Feb 2, 2026 |
| Jan 30, 2026 | Adrian W Quartel Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -4,533 | $8.83 | $40k | 9,723 | Feb 2, 2026 |
| Jan 30, 2026 | Timothy J. Sangiovanni SVP, Finance & Corp Controller | SOpen-market sale Common Stock10b5-1 | -1,750 | $8.82 | $15k | 20,924 | Feb 2, 2026 |
| Jan 30, 2026 | Joshua Schafer CCO | SOpen-market sale Common Stock10b5-1 | -3,375 | $8.83 | $30k | 37,444 | Feb 2, 2026 |
| Jan 30, 2026 | Rahsaan Thompson Chief Legal & Compliance | SOpen-market sale Common Stock10b5-1 | -4,080 | $8.83 | $36k | 49,919 | Feb 2, 2026 |
| Feb 2, 2026 | Neil F. McFarlane President and CEO | SOpen-market sale Common Stock10b5-1 | -91,000 | $9.38 | $853k | 364,350 | Feb 2, 2026 |
| Jan 31, 2026 | Joshua Schafer CCO | MOption exercise Common Stock10b5-1 | +35,334 | - | - | 72,778 | Feb 2, 2026 |
| Jan 29, 2026 | Neil F. McFarlane President and CEO | AGrant or award Restricted Stock Unitderivative10b5-1 | +125,000 | $0.00 | $0 | 125,000 | Feb 2, 2026 |
| Jan 29, 2026 | Adrian W Quartel Chief Medical Officer | AGrant or award Restricted Stock Unitderivative10b5-1 | +37,500 | $0.00 | $0 | 37,500 | Feb 2, 2026 |
| Jan 29, 2026 | Rahsaan Thompson Chief Legal & Compliance | AGrant or award Restricted Stock Unitderivative10b5-1 | +37,500 | $0.00 | $0 | 37,500 | Feb 2, 2026 |
| Jan 31, 2026 | Timothy J. Sangiovanni SVP, Finance & Corp Controller | MOption exercise Common Stock10b5-1 | +11,666 | - | - | 32,590 | Feb 2, 2026 |
| Jan 30, 2026 | Timothy J. Sangiovanni SVP, Finance & Corp Controller | MOption exercise Restricted Stock Unitderivative10b5-1 | -6,333 | $0.00 | $0 | 12,667 | Feb 2, 2026 |
| Jan 29, 2026 | Neil F. McFarlane President and CEO | AGrant or award Stock Option (right to buy)derivative10b5-1 | +250,000 | $0.00 | $0 | 250,000 | Feb 2, 2026 |
| Jan 29, 2026 | Rahsaan Thompson Chief Legal & Compliance | AGrant or award Stock Option (right to buy)derivative10b5-1 | +75,000 | $0.00 | $0 | 75,000 | Feb 2, 2026 |
| Jan 29, 2026 | Adrian W Quartel Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative10b5-1 | +75,000 | $0.00 | $0 | 75,000 | Feb 2, 2026 |
| Jan 29, 2026 | Joshua Schafer CCO | AGrant or award Restricted Stock Unitderivative10b5-1 | +37,500 | $0.00 | $0 | 37,500 | Feb 2, 2026 |
| Jan 30, 2026 | Adrian W Quartel Chief Medical Officer | MOption exercise Restricted Stock Unitderivative10b5-1 | -11,333 | $0.00 | $0 | 22,667 | Feb 2, 2026 |
| Jan 30, 2026 | Rahsaan Thompson Chief Legal & Compliance | MOption exercise Restricted Stock Unitderivative10b5-1 | -11,333 | $0.00 | $0 | 22,667 | Feb 2, 2026 |
| Jan 29, 2026 | Joshua Schafer CCO | AGrant or award Stock Option (right to buy)derivative10b5-1 | +75,000 | $0.00 | $0 | 75,000 | Feb 2, 2026 |
| Jan 31, 2026 | Neil F. McFarlane President and CEO | MOption exercise Restricted Stock Unitderivative10b5-1 | -233,334 | $0.00 | $0 | 233,333 | Feb 2, 2026 |
50 of 82 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Thomas Andersondirector
- John B Bodedirector
- Douglas W Calderdirector
- R. LaDuane CliftonCFO & Treasurer
- Tamara A Favoritodirector
- Neil F. McFarlanePresident and CEO
- Adrian W QuartelChief Medical Officer
- Justin A RenzCFO
- Timothy J. SangiovanniSVP, Finance & Corp Controller
- Joshua SchaferCCO
- Alicia Secordirector
- Alvin Shihdirector
- Rahsaan ThompsonChief Legal & Compliance
- Corey Michael Wattondirector
Questions about ZVRA
Answered from the filings on this page, as of the latest one.
Are insiders buying ZVRA?
As of Aug 17, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 2 open-market sells worth $613k by 2 insiders at ZEVRA THERAPEUTICS, INC. in the last 90 days, net -$613k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade ZVRA on the open market?
Rahsaan Thompson (Chief Legal & Compliance) sold $475k of ZVRA on Aug 14, 2026 and filed the Form 4 on Aug 17, 2026. InsiderTell scored 40 (moderate), under a 10b5-1 plan, with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at ZEVRA THERAPEUTICS, INC.?
14 people have filed a Form 4 at ZEVRA THERAPEUTICS, INC., among them Thomas Anderson (director), John B Bode (director), Douglas W Calder (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.